Ancillary Educational Events

Point-Counterpoint: Investigators Discuss and Debate Clinical Questions and Controversies in Non-Small Cell Lung Cancer 

Date and Time: Friday, June 2, 2017, 7:00 PM (Registration and dinner being at 6:30 PM)

Location: Grand Ballroom, Hilton Chicago

CME Provider and Supporter(s): This event is organized and accredited by Research to Practice and is supported by an educational grant provided by Lilly.

Registration and Contact Information: Register for the event. Email for additional information call (800) 233-6153.

Event Summary: This symposium will focus on the discussion of challenging clinical situations identified by a cohort of 10 community-based oncologists. In the months prior to the meeting, Research To Practice and the invited faculty will consult with this group of physicians who care for patients with NSCLC to identify clinical situations and/or ambiguous data sets for which they would like to receive expert feedback/perspective. During each of the 5 modules at the event, one faculty member will deliver a presentation reviewing data sets and ongoing trials that inform decision-making related to the scenarios identified. Following each presentation, a panel discussion will be introduced and in situations where faculty members express divergent management approaches, two experts will be invited to provide their rationales in a point/counterpoint style “debate.” To maintain audience interest, attendees will participate in a pre-meeting survey utilizing networked iPads which will include questions related to the topics that will be discussed. The results will be displayed throughout the event. 

Faculty:
Leora Horn, MD, MSc
Vanderbilt University Medical Center

Corey J Langer, MD
Perelman School of Medicine, University of Pennsylvania

Gregory J Riely, MD, PhD
Memorial Sloan Kettering Cancer Center

Jean-Charles Soria, MD, PhD
Institut Gustave Roussy

Neil Love, MD- Moderator
Research To Practice

* Additional faculty to be announced

Making Critical Decisions in EGFR-Mutant Lung Cancers: How to Apply Evidence to Decide What to Do When the Patient is There in Front of You

Date and Time: Friday, June 2, 2017, 7:00 PM (Registration and dinner being at 6:30 PM)

Location: Continental Ballroom, Hilton Chicago

CME Provider and Supporter(s): This event is organized and accredited by Physicians’ Education Resource, LLC (PER) and is supported by an educational grant provided by AstraZeneca.

Registration and Contact Information: Register for the eventEmail for additional information or call (609) 378-3701.

Event Summary:
Decision-making in the context of treating patients with EGFR-mutant lung cancers has gotten increasingly complex with the recent expansion of therapeutic options. Selecting appropriate therapy along the disease continuum is based on a number of factors, including the ability to facilitate tumor tissue testing, the type of EGFR mutation identified, when to rebiopsy and/or retest for molecular markers (and the method by which to do so), when to switch therapies, what constitutes relapse, selecting the best approach at the time of acquired drug resistance, mitigation of treatment-related toxicities, and the management of CNS metastases are complex scenarios that continue to evolve in treatment today. This highly-interactive educational activity will discuss the recent evidence in treating EGFR-mutant lung cancers along the continuum, feature multiple question-and-answer sessions to apply information, and help you in selecting your approach when facing a real patient with lung cancer. iPad technology will be provided to increase interaction with the faculty and enhance learning.

Faculty:
Mark Kris, MD - Chair
Memorial Sloan Kettering Cancer Center

Geoffrey Oxnard, MD
Dana-Farber Cancer Institute

Kathryn Beal, MD
Memorial Sloan Kettering Cancer Center

Lecia Sequist, MD
Massachusetts General Hospital

EXPERT EXCHANGE: Advances in Biomarker-Driven Immune Checkpoint Blockade for Selected Types of Solid Tumors

Date and Time: Friday, June 2, 2017, 7:00 PM (Registration and dinner begin at 6:30 PM)

Location: International South Ballroom, Hilton Chicago

CME Provider and Supporter(s): This event is organized and accredited by Creative Educational Concepts and is supported by an educational grant provided by AstraZeneca.

Registration and Contact Information: Register for the event. Email for additional information call (859) 360-1717 ext. 1100.

Event Summary:
Recent advances in cancer immunotherapy, particularly immune checkpoint blockade targeting CTLA-4 and PD-1/PD-L1 pathways, have improved outcomes for many patients with advanced malignancies. Immunomodulatory monoclonal antibodies are being studied for a variety of tumor types. These agents may be used in combination on nonredundant pathways to synergistically augment tumor response. This engaging, interactive symposium will feature clinically relevant debates between experts in the field of solid tumor immunotherapy within the context of patient case-based scenarios. After an update on the current state of immune checkpoint inhibitors in selected types of solid tumors, experts will debate the emerging concepts involved in immunotherapy combinations and the role of prognostic and predictive biomarkers of response. Attendees will participate in the discourse by voting for a “point” or “counterpoint” position on audience response keypads prior to and after evidence-based faculty member discussions. This activity will provide continuing education credit for physicians, nurses, and pharmacists.

Faculty:
Jeffrey S. Weber, MD, PhD - Chair
Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center

Robert L. Ferris, MD, PhD
University of Pittsburgh Cancer Institute

Naiyer A. Rizvi, MD
Columbia University Medical Center

Joaquim Bellmunt, MD, PhD
Harvard Medical School, Dana-Farber Cancer Institute

Show Me the Data: The Experts Weigh-In on Evidence to Support Strategies for Classic Clinical Scenarios in RCC

Date and Time: Friday, June 2, 2017, 7:00 PM (Registration and dinner begin at 6:30 PM)

Location: International North, Hilton Chicago

CME Provider and Supporter(s): This event is organized and accredited by Physicians’ Education Resource, LLC (PER) and is supported by an educational grant provided by Exelixis.

Registration and Contact Information: Register for the EventEmail for additional information or call (609) 378-3701.

Event Summary:
The management of renal cell carcinoma (RCC) has undergone dramatic changes recently with multiple new approvals in the metastatic setting. In addition to treatment paradigm shifts that continue to occur in advanced settings, there also remain important unmet clinical needs specific to non-clear cell RCC and in the adjuvant setting. This timely educational activity will challenge expert faculty to show particular evidence that informs the treatment decisions they make, in parallel with capturing and assessing learners’ knowledge, skills, and attitudes toward RCC management¾knowing that all contribute to their ability to improve and optimize patient outcomes. The program format is intended to allow participants to reflect on how they arrive at the treatment decisions they make, how their decisions compare with the experts, whether they have a deep understanding of landmark trial results, and how to best contextualize evidence to optimize considerations at key decision points along the RCC treatment continuum. During this case-based symposium, clinical scenarios will be broached at key junctures in care with the understanding that real-world patients cannot always be bucketed neatly, and situations characterized simply as “lines of therapy are many times more aptly categorized as “key decision” points. Faculty will be present onstage throughout the program for a structured discussion about these key decision points in the care of patients with RCC.

Faculty:
Toni Choueiri, MD- Chair
Dana-Farber Cancer Institute

Thomas E. Hutson, DO, PharmD, FAC
Texas Oncology at Baylor Sammons Cancer Center

Lauren C. Harshman, MD
Dana-Farber Cancer Institute

Daniel James George, MD
Duke Cancer Center

Nizar M. Tannir, MD, FACP
The University of Texas MD Anderson Cancer Center

Thomas Powles, MBBS, MRCP, MD
Barts Cancer Institute

Management of HR-Positive Advanced Breast Cancer: Is There A Right Sequence?

Date and Time: Friday, June 2, 2017, 7:00 PM (Registration and dinner begin at 6:30 PM)

Location: Regency AB, Hyatt Regency Chicago

CME Provider and Supporter(s): This event is organized and accredited by Medscape and is supported by an educational grant provided by AstraZeneca

Registration and Contact Information: Email for additional information 

Event Summary:
Rapidly evolving data in HR+ metastatic breast cancer are challenging physicians to implement new paradigms in practice. This proposed case-based approach will provide expert practice-level support to engage and educate physicians in order to raise awareness and provide practical strategies in a changing clinical environment in front-line and relapsed settings. Key to this is the underlying need to individualize patient treatment based on identifiable clinical characteristics which will be highlighted and discussed within each case presentation in the context of current clinical evidence and clinical best-practice. The initial presentation will review recent progress, and subsequent presentations will use clinical data to contextualize individual case presentations and address ‘best-fit’ options for each case. Topics will include suitability for endocrine monotherapy, combination endocrine/CDK46 inhibitor therapy, patient selection strategies and management of treatment-emergent adverse events, and will provide attending and on-line physicians with recommended clinical best-practice solutions to challenges they face in practice.

Faculty:
Joyce O’Shaughnessy, MD
Baylor University Medical Center, Texas Oncology, US Oncology 

Kerin Adelson, MD
Smilow Cancer Hospital, Yale Cancer Center

Professor Peter Schmid, MD, PhD, FRCP
St Bartholomew Hospital London, Barts Cancer Institute 

ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs along the Disease Continuum

Date and Time: Saturday, June 3, 2017, 7:00 PM (Registration and dinner begin at 6:30 PM)

Location: Chicago 6 & 7, Sheraton Grand Chicago

CME Provider and Supporter(s): This event is organized and accredited by Physicians’ Education Resource, LLC and is supported by an educational grant provided by Ariad Pharmaceuticals, Inc.

Registration and Contact Information: Register for the event. Email for additional information or call (609) 378-3701.

Event Summary:
The treatment landscape for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) has been shaped by the emergence of targeted therapies that have demonstrated clinical efficacy. However, many perplexing challenges in the treatment of ALK-positive NSCLC remain, including the frequent development of treatment resistance and emergence of brain metastases. Treatment-related toxicities present another layer of complexity in the management of these patients, as do determination of appropriate sequencing of therapy and selection of optimal testing strategies. This case-based educational activity, featuring leading experts in management of patients with NSCLC, has been developed to help clinicians with the management of these challenges. Multiple topics will be explored, including management of treatment-naïve patients, treatment approaches for patients who have relapsed, and testing considerations along the disease spectrum. In addition to panel case discussions, there will be opportunities for the audience to present questions to the faculty.  

Faculty:
David Gandara, MD - Chair
University of California Davis Comprehensive Cancer Center

David Ross Camidge, MD, PhD
University of Colorado Cancer Center

Justin F. Gainor, MD
Harvard Medical School, Massachusetts General Hospital

Christine M. Lovly, MD, PhD
Vanderbilt-Ingram Cancer Center

Howard (Jack) West, MD
Swedish Cancer Institute

EXPERT EXCHANGE: Management of Advanced EGFR Mutation-Positive NSCLC – Making Bold Strides Toward True Precision Medicine

Date and Time: Saturday, June 3, 2017, 7:00 PM (Registration and dinner begin at 6:30 PM)

Location: International South Ballroom, Hilton Chicago

CME Provider and Supporter(s): This event is organized and accredited by Creative Educational Concepts and is supported by an educational grant provided by AstraZeneca.

Registration and Contact Information: Register for the eventEmail for additional information or call (859) 360-1717 ext. 1100

Event Summary: The discovery of epidermal growth factor receptor gene (EGFR) and subsequent development of EGFR-tyrosine kinase inhibitors (TKIs) have changed the treatment paradigm of EGFR mutation-positive NSCLC.  However, many questions still remain on how to best move forward in this new era of precision medicine. This interactive symposium will feature clinically relevant debates between experts in the field of NSCLC within the context of patient case-based scenarios. Faculty will provide evidence-based answers and expert perspectives to clinical questions regarding the role of specific EGFR mutation type (exon 19 vs. 21) in TKI selection, the utility of ctDNA testing to detect EGFR mutations, optimal strategies for treating T790M acquired resistance, and clinical treatment implications of emerging data. Attendees will participate by voting for a “point” or “counterpoint” position on audience response keypads prior to and after evidence-based faculty member discussions. This activity will provide continuing education credit for physicians, nurses, and pharmacists.

Faculty:
Suresh S. Ramalingam, MD- Chair
Emory University School of Medicine

Pasi A. Jänne, MD, PhD
Harvard Medical School, Dana-Farber Cancer Institute

Mark G. Kris, MD, FACP, FACCP
Memorial Sloan-Kettering Cancer Center, Cornell University Medical College

Tony S.K. Mok, BMSc, MD, FRCPC
The Chinese University of Hong Kong

Lecia V. Sequist, MD, MPH
Harvard Medical School, Massachusetts General Hospital Cancer Center

Breaking New Ground in AML: Practical Applications of Emerging Treatment Options

Date and Time: Saturday, June 3, 2017, 7:00 PM (Registration and dinner begin at 6:30 PM)

Location: Regency AB, Hyatt Regency Chicago

CME Provider and Supporter(s): This event is organized and accredited by MediCom Worldwide, Inc and is supported by educational grants provided by Agios Pharmaceuticals Inc., Astellas, Celgene Corporation, Helsinn, and Jazz Pharmaceuticals.

Registration and Contact Information: Register for the eventEmail for additional information or call (800) 408-4242.

Event Summary: The medical landscape of acute myeloid leukemia (AML) is rapidly evolving, as evidenced by the recent explosion of clinical trials, updated practice guidelines, and the World Health Organization revised diagnostic and prognostic criteria. Coupled with a multitude of therapies in late-stage development, staying up-to-date can present major challenges to practitioners seeking to remain current with the latest clinical evidence in AML.  Our panel of nationally-recognized thought leaders will provide an opportunity for interaction and engagement with the audience, allowing sufficient time to present individual questions and clinical challenges for discussion. At the close of this activity, Dr. Garcia-Manero will present a series of case vignettes focused on how emerging agents are anticipated to fit into current practice once approved.

Faculty:
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center

Richard Stone, MD
Dana-Farber Cancer Institute

Jeffrey E. Lancet, MD
Moffitt Cancer Center 

Elli Papaemmanuil, PhD
Memorial Sloan Kettering Cancer Center

Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder Cancers

Date and Time: Saturday, June 3, 2017, 7:00 PM (Registration and dinner being at 6:30 PM)

Location: International North, Hilton Chicago

CME Provider and Supporter(s): This event is organized and accredited by Physicians’ Education Resource, LLC (PER) and is supported by an educational grant provided by AstraZeneca.

Registration and Contact Information: Register for the EventEmail for additional information or call (609) 378-3701.

Event Summary: As exciting as the initial data has been recently regarding immuno-oncology agents in cancer care, there remains several highly-anticipated trials with newer compounds currently undergoing late-stage evaluation. Importantly, much discussion remains on many hot topics in the field, including how we can best personalize immuno-oncology strategies via the use of PD-L1 and other biomarkers, how these approaches can be optimally combined with current/emerging immuno-oncology and targeted agents, and how to practically apply combination strategies in the context of proactive mitigation of predictable treatment-related toxicities. This educational activity will highlight the clinical context of noteworthy evidence in immuno-oncology, with discussion of how to apply numerous new data sets to unique patients. iPad technology will be provided to increase interaction with the faculty and enhance learning.

Faculty:
Roy Herbst, MD, PHD – Chair
Yale Cancer Center

Julie Brahmer, MD
Sidney Kimmel Comprehensive Cancer Center

Robert Ferris, MD, PhD
University of Pittsburgh Cancer Institute

Daniel Petrylak, MD
Yale Cancer Center

Jeffrey Weber, MD, PhD
NYU Langone Medical Center